Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Panorex study whets appetite for more data

After five years, Centocor Inc. presented encouraging findings from its study of the Panorex monoclonal antibody in colorectal cancer, but indications are that both the company and clinicians will want to see the results replicated in a larger study.

As of now, the company only plans to use the data for a January 1994 marketing filing in Germany.

CNTO and its marketing partner, Wellcome plc, haven't

Read the full 660 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE